- Coated pellets with delayed-release glucose for prevention of hypoglycemic episodes2016 | Publication without faculty affiliation
- Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience2015 | First Faculty of Medicine
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study2017 | First Faculty of Medicine
- Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel2014 | First Faculty of Medicine
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study2015 | First Faculty of Medicine
- Preparation of pellets with controlled release of glucose as prevention of hypoglycaemia in paediatric patients2015 | Publication without faculty affiliation
- Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis2021 | Publication without faculty affiliation
- Efficacy and safety of delayed-release oral mesalazine at 4.8g/D (800mg tablet) in the treatment of moderately active ulcerative colitis: Results of the Ascend III studyPublication without faculty affiliation
- Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate2015 | First Faculty of Medicine
- Formulation of cores for the controlled release of glucose for prevention of hypoglycemia in diabetes patients2014 | Publication without faculty affiliation
- Interdiction of hypoglycemia in diabetic children by multiparticulate dosage form with controlled glucose release2016 | Publication without faculty affiliation
- Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies2015 | First Faculty of Medicine
- Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Acrive Ulcerative Colitis2009 | First Faculty of Medicine
- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies2017 | First Faculty of Medicine
- Pharmacs with pulsatile repase2015 | Publication without faculty affiliation
- Mechanisms of chemical communication: the role of Major Urinary Proteins2009 | First Faculty of Medicine, Faculty of Science, Faculty of Mathematics and Physics
- Thin films of cross-linked polylactic acid as tailored platforms for controlled drug release2021 | Faculty of Mathematics and Physics
- A Study of Compressibility, Compactability and Mucoadhesivity of Tableting Materials for Matrix Systems Based on Chitosan2021 | Faculty of Pharmacy in Hradec Králové